Jong-Ho Hong
Chief Executive Officer chez KUKJEON PHARMACEUTICAL CO., LTD
Fortune : 97 M $ au 31/03/2024
Profil
Jong-Ho Hong is currently the Chief Executive Officer at Kukjeon Pharm Co., Ltd.
and the Chief Executive Officer & Director at Kukjeon Pharmaceutical Co., Ltd.
He has a graduate degree from Sogang University and an undergraduate degree from Sungkyunkwan University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/04/2024 | 21 373 361 ( 43,56% ) | 97 M $ | 31/03/2024 |
Postes actifs de Jong-Ho Hong
| Sociétés | Poste | Début |
|---|---|---|
| KUKJEON PHARMACEUTICAL CO., LTD | Chief Executive Officer | - |
Kukjeon Pharm Co., Ltd.
 Kukjeon Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Kukjeon Pharm Co., Ltd. manufactures medicines and antibiotics. The firm’s products include celecoxib, choline alfoscerate, dibucaine, enoxolone, eperisone HCL, epinastine HCL, hinokitiol and nizatidine. The company was founded on July 26, 1995 and is headquartered in Anyang-si, South Korea. | Chief Executive Officer | - |
Formation de Jong-Ho Hong
| Sogang University | Graduate Degree |
| Sungkyunkwan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Kukjeon Pharm Co., Ltd.
Kukjeon Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Kukjeon Pharm Co., Ltd. manufactures medicines and antibiotics. The firm’s products include celecoxib, choline alfoscerate, dibucaine, enoxolone, eperisone HCL, epinastine HCL, hinokitiol and nizatidine. The company was founded on July 26, 1995 and is headquartered in Anyang-si, South Korea. | Health Technology |
| Kukjeon Pharmaceutical Co., Ltd. |
